Three newly identified helper T cell peptides from the WT1 tumor protein dramatically enhanced the cancer-killing ability of WT1 vaccines in mice by boosting killer T cell generation and creating long-lasting immune memory.
Helper peptides = tumor rejectionAdding 3 WT1 helper peptides to a killer-cell vaccine enabled efficient rejection of WT1-expressing tumors that the killer peptide alone could not achieve
What the researchers found
Three novel WT1 Th peptides strongly enhanced CTL induction, maintenance, and tumor rejection when co-immunized with WT1 CTL peptide in mice.
Why it matters
WT1 is overexpressed in many cancers. Better vaccines incorporating helper peptides could improve cancer immunotherapy outcomes.
The numbers in context
3 Th peptides: WT135-52, WT186-102, WT1294-312; enhanced CTL induction + maintenance; CD44+CD62L- effector memory; improved tumor rejection
How the study worked
Mouse immunization study. Identified WT135-52, WT186-102, and WT1294-312 Th peptides. Co-immunization with WT1 CTL peptide. Tumor challenge with WT1-expressing cells. T cell phenotyping.
Who was studied
C57BL/6 mice immunized with WT1 peptides and challenged with WT1-expressing tumors
What this study cannot tell us
Mouse model. WT1-specific responses in humans may differ. Specific peptides are MHC-restricted and may need human counterparts identified.
How to read the evidence
Well-designed preclinical mouse study using the standard C57BL/6 model with tumor challenge experiments. The identification of three functional helper peptides with clear phenotypic characterization is thorough. Limited by being mouse-only with MHC-restricted peptides that need human equivalents identified.
When this study was published
Published in 2021, this study contributes to the active development of WT1 peptide vaccines, several of which are in clinical trials. The helper peptide approach demonstrated here could inform future clinical vaccine formulations.
The bigger picture
WT1 was ranked the #1 cancer vaccine target by the National Cancer Institute due to its overexpression across many tumor types. Multiple WT1 peptide vaccines are in clinical trials for leukemia, mesothelioma, and other cancers. This study addresses a known weakness of peptide cancer vaccines: they often generate short-lived killer T cell responses that fade before tumors are eliminated. By adding helper peptides that sustain the response and promote memory formation, the researchers provide a blueprint for improving next-generation WT1 vaccines — and potentially peptide cancer vaccines in general.
Questions still open
- Do human equivalents of these mouse helper peptides exist, and can they be incorporated into clinical WT1 vaccines?
- Would combining multiple helper peptides with multiple killer peptides create an even more effective multi-epitope vaccine?
- Can this helper-peptide enhancement approach be applied to other tumor-associated antigen vaccines beyond WT1?
Common questions
What are helper T cells and why do they matter for cancer vaccines?
What is WT1 and why is it a good cancer vaccine target?
Read the original research
Identification of mouse helper epitopes for WT1-specific CD4+ T cells.
Cancer immunology, immunotherapy : CII, 70(11), 3323-3335
Citation
Nakajima, Hiroko; Nakata, Jun; Imafuku, Kanako; Hayashibara, Hiromu; Isokawa, Kazuki; Udaka, Keiko; Fujiki, Fumihiro; Morimoto, Soyoko; Hasegawa, Kana; Hosen, Naoki; Hashii, Yoshiko; Nishida, Sumiyuki; Tsuboi, Akihiro; Oka, Yoshihiro; Oji, Yusuke; Sogo, Shinji; Sugiyama, Haruo. (2021). Identification of mouse helper epitopes for WT1-specific CD4+ T cells.. Cancer immunology, immunotherapy : CII, 70(11), 3323-3335. https://doi.org/10.1007/s00262-021-03003-5